Coloplast A/S Sponsored ADR (OTCMKTS:CLPBY – Get Free Report)’s share price gapped down prior to trading on Friday . The stock had previously closed at $6.98, but opened at $6.82. Coloplast A/S shares last traded at $6.84, with a volume of 4,239 shares traded.
Wall Street Analysts Forecast Growth
Separately, Kepler Capital Markets upgraded shares of Coloplast A/S to a “strong-buy” rating in a report on Wednesday, May 20th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Coloplast A/S presently has a consensus rating of “Hold”.
Get Our Latest Analysis on CLPBY
Coloplast A/S Trading Up 1.4%
Coloplast A/S (OTCMKTS:CLPBY – Get Free Report) last released its earnings results on Tuesday, August 18th. The company reported $0.10 EPS for the quarter, hitting analysts’ consensus estimates of $0.10. The company had revenue of $1.14 billion for the quarter, compared to analysts’ expectations of $1.11 billion. Coloplast A/S had a net margin of 9.68% and a return on equity of 38.81%. As a group, equities analysts forecast that Coloplast A/S Sponsored ADR will post 0.38 earnings per share for the current year.
About Coloplast A/S
Coloplast A/S is a global developer and manufacturer of medical devices and services focused on intimate healthcare. The company specializes in solutions designed to assist individuals with chronic medical conditions, aiming to improve quality of life through innovative products. Coloplast’s offerings span ostomy care, continence care, wound and skin care, and interventional urology, targeting patients who require long-term support and specialized treatments.
In its ostomy business, Coloplast provides pouches, skin barriers and accessories for patients who have had surgical procedures to divert bodily waste.
Further Reading
- Five stocks we like better than Coloplast A/S
- Advance Auto Parts Plunged, But Its Turnaround Is Still Working
- Is Palo Alto Networks Priced for Perfection Again as AI Security Demand Accelerates?
- Meta Platform’s Legal Issues Could Become Much More Than A Q2 Earnings Headache
- Marvell Constructs an AI Moat With Alphabet Warrants
Receive News & Ratings for Coloplast A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coloplast A/S and related companies with MarketBeat.com's FREE daily email newsletter.
